FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

Learning Objectives After completing this course, the reader will be able to: Describe the bevacizumab mechanism of action.List the current bevacizumab indications.Discuss the role of bevacizumab in the treatment of specific non-small cell lung cancer histologies.Describe the clinical trial design leading to bevacizumab approval by the FDA.Identify the major adverse events associated with bevacizumab treatment. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com